Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

FreeStyle Libre Continuous Glucose Monitoring

Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

Diabetes Technology Meeting 2020 - Trisha Shang, Jennifer Y. Zhang, B. Wayne Bequette, Jennifer K. Raymond, Gerard Coté, Jennifer L. Sherr, Jessica Castle, John Pickup, Yarmela Pavlovic, Juan Espinoza, Laurel H. Messer

FreeStyle Libre 2 System (CGM)

Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus - ScienceDirect

Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project

FreeStyle Libre 2 Reader - Healthcare Home Medical Supply USA

FreeStyle Libre 2 Continuous Glucose Monitor

PDF) Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations

FreeStyle Libre 2 Continuous Glucose Monitor

Intermittently scanned continuous glucose monitoring is associated with high satisfaction but increased HbA1c and weight in well‐controlled youth with type 1 diabetes - Charleer - 2020 - Pediatric Diabetes - Wiley Online Library

The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Berlin, Germany—February 20–23, 2019

FreeStyle Libre 2 Continuous Glucose Monitor

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes